Kornimate/medical-research-clean huggingface dataset:
transient thermal behavior and diabetic foot

Conditions: Diabetic Patients Type 1 and 2; Podologic Grade From 0 to 3

Summary: in our study, the investigators propose to analyze the transient thermal responses taken at the level of the sole of the foot, following the application of a cold stimulus. by combining a spatio-temporal analysis of these temperature fields and a thermal modeling of the heat transfer in the thickness of the foot, the investigators want to highlight differences between healthy feet vs. pathological feet. therefore, the investigators will determine the transient thermal responses at the level of the sole of the foot and correlate them with the podological grade.

both plants of the patient's feet will be observed by a thermal camera. static observations (taking a single image), or dynamic (taking a series of images) of the foot, will be made. in the latter case, the observation will be done after a brisk walk of 6 min. the instruction given to patients will be to go the furthest in 3 min and then come back in 3 min, all while walking. the observation will be made by cameras without contact. these thermal cameras are non-invasive and non-ionizing, there is no risk related to their use. the camera will be placed on a tripod, a few tens of centimeters from the foot, and connected to a laptop (for the images acquisition). a wooden box, painted black, will be placed around both feet to protect the scene from parasitic thermal radiation that can disturb temperature variations. foam will protect the skin / wood interface. electric resistances, fixed on the box, will be placed in the field of vision of the thermal camera to guarantee the good treatment of the images. these resistors will never be in contact with the patient. the area filmed by the camera will be limited to the sole arch and, sometimes, the hand of patients to see if a thermal anomaly is also present on this member.

Eligibility criteria:
inclusion criteria: * diabetic subjects (type 1 and 2) * age above 18 years old * able to walk * affiliate to insurance regimen exclusion criteria: * unable to stay motionless * pregnancy * subjects with feet wound

Keywords: infrared thermography diabetic foot six minutes walking test microcirculation
personalized self-management training compared to standardized self-management training in colorectal cancer patients.

Conditions: Colorectal Cancer; Healthy Lifestyle; Behavior, Health; Health Behavior

Summary: this is a phase 2 prospective, randomized, controlled, double-arm study to assess personalized self-management training (psmt) intervention efficacy and patient experiences compared to standardized self-management training (ssmt). a total of 120 colorectal cancer (crc) patients will be enrolled and randomized 1:1 to complete a 6-week self-management training program (either psmt or ssmt) to be carried out by licensed occupational therapists with doctoral training. this study aims to examine whether psmt is more effective in increasing adherence to healthy behavior recommendations compared to ssmt in crc patients.


Eligibility criteria:
inclusion criteria: 1. age ≥18 years at the time of consent. 2. history of stage i-iii colorectal cancer (crc) within the past 12 months prior to enrollment. 3. ability to speak, write, and read english sufficiently to allow for program participation. 4. identified by self-report as having willingness and interest to work on at least one lifestyle-related risk factor. lifestyle-related risk factors include diet, physical activity, body composition, alcohol use. 5. scoring ≤3.5 on the world cancer research fund/american institute for cancer research (wcrf/aicr) health behavior adherence scale (table 1) consistent with moderate to low adherence to healthy behavior recommendations (hbrs). 6. written informed consent obtained from subject and ability for subject to comply with the requirements of the study. exclusion criteria: 1. cognitive or mental impairments that in the opinion of the principal investigator or study physician would hinder the program participation. 2. planning to have active anti-cancer treatment (including radiation, chemo, and/or major surgery) within 6 months after initial interventional or control session. long-term hormonal/biologic therapy is acceptable. 3. known metastatic disease (stage iv cancers).

Keywords: self-management training
surgical or conservative treatment of sportsman hernia

Conditions: Groin Pain

Summary: five to ten percent of athletes and physical active adults are suffering chronic groin pain. the most common diagnoses are adductor tendinitis, sportsman hernia and osteitis pubis. sportsman hernia is not a real hernia in the groin, but overuse injury of the groin muscles and tendons. no evidence-based treatment of this disabling condition has been found so far. experimental surgical treatments are based on various hernioplasties. laparoscopic extraperitoneal hernioplasty (tep) is a mini-invasive and effective method to heal sportsman hernia in non-randomized cohorts.

this prospective randomized study investigates the effect of active conservative treatment (rest, physical treatment, corticosteroid injections, anti-inflammatory analgesics) versus surgery (laparoscopic tep) on the healing of sportsman hernia. diagnosis of sportsman hernia is always based on careful clinical examination and magnetic resonance imaging. 25 patients with sportsman hernia are randomized into conservative treatment and 25 patients in surgery. the duration of follow-up is 1 year. the main end-point of treatments is disappearing of chronic groin pain (visual analogue scale, entering to sports).

Eligibility criteria:
inclusion criteria: * severe groin pain lasting \> 6 months * sportsman hernia exclusion criteria: * other diagnosis ruled out by mri and clinical examination

Keywords: groin pain sportsman hernia osteitis pubis laparoscopic surgery
pilot randomized trial of ambulatory exercise in pulmonary hypertension

Conditions: Pulmonary Arterial Hypertension

Summary: the researchers are investigating if changing an individual's behaviors may have an impact on outcomes for patients with pulmonary arterial hypertension (pah). this research will test the efficacy of a home-based exercise program to improve exercise tolerance and physical activity.


Eligibility criteria:
inclusion criteria: * diagnosis of group 1 pulmonary atrial hypertension (pah) diagnosed during right heart catheterization (rhc) according to who criteria 28 * who functional class ii to iii * stable clinical condition, with no change in medical therapy for pulmonary arterial hypertension (pah) for at least 3 months before enrollment * planned follow-up at university of michigan hospital centers over at least 1 year * if enrolled in clinical trial, must be in open-label extension stage on stable medications for at least 3 months. * competent to give informed consent * have computer and internet access exclusion criteria: * life expectancy under 1 year * co-morbidities which limit physical activity to a severe degree (i.e., permanently wheelchair bound, musculoskeletal disorders, recent myocardial infarction, unstable arrhythmia) * current substance abuse, and/or a severe psychiatric disorder (including severe depression, psychosis, or dementia) which limits the patient's ability to follow the study protocol * recently completed (\<6 months), current enrollment or planned enrollment in pulmonary rehab. * ≥30 minutes of exercise, ≥ 1 day per week for the previous 3 months * six-minute walk distance \ 550 meters * moderate or severe obstructive lung disease forced expiratory volume/forced vital capacity (fev1/fvc) \< 70% and fev1 \< 65% of predicted value after bronchodilator administration). * moderate or severe restrictive lung disease (total lung capacity \< 60% predicted value). * arterial oxygen saturation (spo2) \<88% during 6-minute walk test on baseline home oxygen prescription if applicable or spo2 \<80% if uncorrected shunt. * history of exercise-induced syncope or arrhythmias. * pregnancy or lactation * non-english speaking

Keywords: exercise six-minute walk heart rate monitor
sitagliptin and glucagon counterregulation

Conditions: Type 2 Diabetes

Summary: to evaluate the effect of dpp-4 inhibition on glucagon counter-regulatory mechanisms at moderate hypoglycemia in metformin-treated subjects with t2dm

the glucagon response to mild (3.0 mmol/l) hypoglycemia with and without dpp-4 inhibition by sitagliptin will be evaluated in elderly subjects with metformin treated type 2 diabetes to explore whether dpp-4 inhibition affects glucagon counter-regulation.

Eligibility criteria:
inclusion criteria: 1. written consent has been given. 2. patients with metformin treated t2dm (metformin dose \>0,5 g/day and stable during the preceding 3 months) 3. age \>65 years. 4. hba1c 6.0-8.5% (43-67 mmol/mol; inclusive) at visit 1. 5. ability to complete the study exclusion criteria: 1. a history of any secondary forms of diabetes, e.g., cushing's syndrome and acromegaly. 2. type 2 diabetes, positive gad antibodies 3. egfr \<60 ml/min 4. acute infections which may affect blood glucose control within 4 weeks prior to visit 1 5. any history of recent (\<2 weeks) recurrent or severe hypoglycemic episodes. 6. liver disease such as cirrhosis or chronic active hepatitis 7. history of coronary heart disease or heart failure class iii or iv 8. donation of one unit (500 ml) or more of blood, significant blood loss equaling to at least one unit of blood within the past 2 weeks or a blood transfusion within the past 8 weeks. 9. treatment with growth hormone of chronic oral or parenteral corticosteroid treatment (\> 7 consecutive days of treatment) within 8 weeks prior to visit 1. 10. use of other investigational drugs at visit 1 or within 30 days of visit 1, unsuitable for the study
covid-19: the effectiveness of free face mask distribution

Conditions: Covid19

Summary: the investigators will carry out a randomised trial of free face mask distribution in stovner district, oslo, norway. ten grocery stores will serve as study sites. over three weeks the stores will be randomised daily to having "corona hosts" outside their entrance, handing out face masks to customers. the investigators will compare the proportion of customers who wear face masks as they enter the store in stores with or without face mask distribution.


Eligibility criteria:
all grocery stores in the stovner district are eligible as long as they have not, or only sporadically, had free distribution of face masks previously. at the customer level, we will only include those 12 years or older (age based on the outcome assessor's judgement).

Keywords: face masks infection control behavioral intervention
secukinumab study in psoriasis exploring pruritus intensity and lesional biomarkers

Conditions: Psoriasis

Summary: the study is designed to explore the kinetics of psoriasis symptoms, pruritus intensity and lesional biomarkers.

all subjects will undergo a 16 week run-in phase (open label). at week 16, an evaluation of the pasi response will be performed. patients who achieve a pasi reduction of less than 98 percent will complete the study at week 16 and be referred to routine clinical care for psoriasis by the investigator. patients who achieve extensive remission (pasi reduction by 98-100 percent) at week 16 will enter the randomized withdrawal phase (blinded) where they will be randomized to receive either secukinumab or matching placebo and will complete the study at week 32.

Eligibility criteria:
key inclusion criteria: * chronic moderate to severe plaque type psoriasis as diagnosed by a qualified physician at least 6 months prior to baseline and with a pasi score \> 10 at baseline. * psoriasis patients with pruritus intensity of ≥ 30 on a 100-point vas, with a recall period of 24h as part of the pga-cp, both, at screening and at baseline. key exclusion criteria: * underlying conditions other than psoriasis which in the opinion of the investigator currently cause or influence pruritus of the skin (e.g. drug induced pruritus, renal insufficiency, diabetes). * forms of psoriasis other than chronic plaque-type (e.g., pustular, erythrodermic, and guttate) at screening or study start. * ongoing use of prohibited psoriasis and non-psoriasis treatments. washout periods have to be adhered to. if the use of any of the prohibited treatments is required, then the subject may not be included into the study. * pregnancy, breast feeding or inadequate contraception (if necessary)
rituximab in patients with relapsed or refractory ttp-hus

Conditions: Thrombotic Thrombocytopenic Purpura; Hemolytic Uremic Syndrome

Summary: the general objective of this study is to assess the efficacy and safety of rituximab in the management of patients with refractory or relapsed thrombotic thrombocytopenic purpura-hemolytic uremic syndrome (ttp-hus). there have been several case reports and case series describing the use of rituximab in patients with ttp-hus; however its use has not been studied in a large trial. it is hypothesized that rituximab may ameliorate the severity of certain cases of ttp-hus by decreasing the number of activity of b-cells which may result in decreased production of the adamts13 protease inhibitor. patients with ttp-hus not responding to standard therapy or patients with relapsed disease may have particular benefit. treatments that decrease the frequency of relapse or shorten the time to remission of ttp-hus will be of benefit by decreasing the need for blood product support.


Eligibility criteria:
inclusion criteria: * any patient 18 years or older diagnosed with relapsed or refractory ttp-hus requiring therapy exclusion criteria: * alternate cause of hemolytic microangiopathy (evidence of dic, malignant hypertension, vasculitis, anti-phospholipid antibody syndrome, post-partum acute renal failure) * congenital or familial ttp * ttp occuring post-stem cell, bone marrow, or solid organ transplant * drug-induced ttp * pregnancy or breast-feeding * history of hepatitis b or c infection * prior rituximab treatment * active or metastatic cancer * other causes of thrombocytopenia such as itp, myelodysplastic syndrome, confirmed or suspected drug-induced thrombocytopenia * refusal to receive blood products * hypersensitivity to blood products, plasma products, murine proteins, or any component of the rituximab formulation * geographic inaccessibility * co-morbid illness limiting life expectancy to less than 2 months independent of ttp * failure to provide written informed consent

Keywords: ttp thrombotic thrombocytopenic purpura hus hemolytic uremic syndrome plasma exchange
caudal block for inguinal hernioplasty in children

Conditions: Postoperative Pain

Summary: this is a prospective, randomized, controlled clinical study designed to determine the effectiveness of caudal block combined with general anesthesia in providing intra- and postoperative analgesia, and its effect on hemodynamic stability and drug consumption.

this prospective, randomized, controlled clinical study will include 70 boys aged 3-5 years scheduled for inguinal herniorrhaphy. participants will be randomized in 1:1 ratio into two groups. the first group will receive general anesthesia for surgery, while the second group will receive general anesthesia in combination with caudal block. postoperative pain, hemodynamic parameters and total consumption of all medicaments in the perioperative period will be monitored. complications and side effects of drugs will be observed as well.

Eligibility criteria:
inclusion criteria: * boys between 3 to 5 years old * scheduled for elective inguinal hernioplasty * without comorbidities and chronic therapy, asa class i * body mass and growth normal for the given age * no allergies * no congenital anomalies and birth complications exclusion criteria: * emergency surgeries * surgeries longer than 60 minutes * acute infections with leucocytosis/leucopenia * acute or chronic diseases * deformities and disorders of spine and nervous system * allergies * pilonidal cyst and/or inflammation in sacral region

Keywords: general anesthesia caudal block pain hemodynamic parameters
allogeneic hematopoietic stem cell transplantation in patients with myelodysplastic syndrome low risk

Conditions: MDS

Summary: comparison of survival in patients with or without a matched donor at 36 months

patients with a matched donor (8/8 at molecular level unrelated donor or matched sibling) received an allogeneic hematopoietic stem cell transplantation. patients without a matched donor received the best available treatment. all patients will be followed at least 36 months or until the end of the study.

Eligibility criteria:
inclusion criteria: 1. signed informed consent 2. classical ipss intermediate 1 or low myelodysplastic syndrome associated with at least one poor prognosis feature: 1. intermediate or higher risk revised ipss 2. rbc transfusion dependent anemia and failure to 2 or more lines or therapy (including epo, lenalidomide or demethylating agent...) 3. thrombocytopenia \< 20 g/l requiring transfusion 4. neutropenia \< 0.5 g/l associated with severe infection (defined as requiring hospitalization) 3. patient aged ≥ 18 and \< 70 years for young patients, 18-45 years, fanconi disease and dyskeratosis should be ruled out 4. patient for whom a transplantation from a matched donor, (8/8 (hla a, b, c, drb1) identical at molecular level)unrelated donor or matched sibling), is considered irrespective of donor availability 5. performance status 0-2 on the eastern cooperative oncology group (ecog) scale (at time of screening) 6. negative pregnancy and adequate contraception (including in male patients wishing to father), if relevant. 7. wash-out of at least 30 days since a previous treatment with vidaza, lenalidomide, epo or any other treatment inducing cytopenias. exclusion criteria: 1. mds classified according to classical ipss as intermediate 2 or high risk 2. transformation in acute myeloid leukemia (aml) 3. severe active infection or any other uncontrolled severe condition. 4. organ dysfunctions including the following * hepatic : total bilirubin \> 2 times upper limit of normal (uln) (except moderate unconjugated hyperbilirubinemia due to intra medullary hemolysis or gilbert syndrome) , alanine transaminase (alt) and aspartate transaminase (ast) \> 3xuln * symptomatic respiratory chronic failure * symptomatic cardiac failure * renal clearance \< 60ml/min 5. prior malignancy (except in situ cervix carcinoma, limited basal cell carcinoma, or other tumors if not active during the last 3 years) 6. mds with the following causal germline disease : fanconi anemia, gata2 related syndromes and telomere disorders

Keywords: low risk mds transplantation
the effect of high dose arginine infusion on hemodynamic and peripheral microcirculation

Conditions: Peripheral Arterial Occlusive Disease

Summary: the aim of this study was to investigate the effect of a 24- hrs l-arginine infusion on hemodynamic and on parameters of microcirculation in patients with peripheral arterial occlusive disease (paod).


Eligibility criteria:
inclusion criteria: * female or male patients receiving peripheral bypass surgery * age between 55 and 75 years exclusion criteria: * metabolic acidosis
a psychoeducational program "balancingmyswing" for patients with bipolar disorder

Conditions: Bipolar Disorder

Summary: the psychoeducation balancingmyswing (bms) program has been developed manually and its feasibility has been tested in our previous study. this 3-year research project aimed to further examine the immediate and lasted effects of bms program for bd, and to assess its knowledge dissemination and the transferability of its evidence-based practice across multiple sites.

the psychoeducation balancingmyswing (bms) program has been developed manually and its feasibility has been tested in our previous study. this 3-year research project aimed to further examine the immediate and lasted effects of bms program for bipolar disorders (bd), and to assess its knowledge dissemination and the transferability of its evidence-based practice across multiple sites. during the first 2 years, a randomized controlled trial was conducted. patients diagnosed with bd were recruited and 104 patients were randomly assigned to treatment as usual (tau) or to 8 bms sessions. a battery of three outcome indicators-social rhythm, illness perception, and symptom severity-were used to examine the effects of the two groups at baseline, after intervention, and every 3 months until half year. in addition, a pre- and post-test quasi-experimental study combined with qualitative design was used to assess the translational feasibility of bms and to explore related barriers and facilitators of implementing bms in clinical settings in the third year. nurses from 4 hospitals received the bms training, and patients with bd received the bms translated in practice were recruited.

Eligibility criteria:
inclusion criteria: * had a dsm-iv(diagnostic and statistical manual of mental disorders-iv) diagnosis of bp-i or ii confirmed through the interviews using the chinese version of the modified schedule of affective disorder and schizophrenia-lifetime. * able to speak and read taiwanese or taiwanese mandarin chinese * had signed a written consent form * agreed to accept the following medication therapy during the study: a mood stabilizer (valproic acid or lithium salts), an antidepressant, second generation antipsychotics, anxiolytics (lorazepam \[\< 8 mg/day\]), and medicine to counteract side effects: extrapyramidal symptoms, tachycardia, and involuntary movement of smooth muscles in the gastrointestinal tract, urinary tract, lungs, etc. exclusion criteria: * required immediate hospitalization * had any comorbidity with substance abuse or were current alcohol or drug abusers, or had been in the previous year * had been diagnosed with an organic psychosis, a neurodegenerative disease, a personality disorder, or impaired cognitive abilities

Keywords: bipolar disorder depression manic illness perception